Abstract #1167
129Xe MRI patterns of lung function in patients with asthma and/or COPD in the NOVELTY study
Helen Marshall1, Laurie J Smith1, Alberto Biancardi1, Guilhem J Collier1, Ho-Fung Chan1, Paul JC Hughes1, Martin L Brook1, Joshua Astley1, Ryan Munro1, Smitha Rajaram1, Andrew J Swift1, David Capener1, Jody Bray1, Ayla K Hussain1, James Ball1, Olly Rodgers1, Demi Jakymelen1, Ian Smith1, Bilal A Tahir1, Madhwesha Rao1, Graham Norquay1, Nick D Weatherley1, Leanne Armstrong1, Latife Hardaker2, Titti Fihn-Wikander3, François-Xavier Blé4, Rod Hughes5, and Jim M Wild1
1Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom, 2Priory Medical Group, York, United Kingdom, 3Evidence Delivery, BioPharmaceuticals Medical, Biopharmaceuticals Business Unit, AstraZeneca, Gothenburg, Sweden, 4Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 5Clinical Development, Research and Early Development, Respiratory & Immunology, AstraZeneca, Cambridge, United Kingdom
Synopsis
There is a need for biomarkers to guide appropriate treatment in patients with clinical features of both asthma and COPD. A broadly-defined population of 164 patients with asthma and/or COPD taking part in the NOVELTY study were recruited from primary care and scanned with 129Xe MRI (ventilation, acinar microstructure and gas exchange measurements). 129Xe MRI global and regional metrics showed significant differences between patients with asthma, asthma+COPD and COPD. 129Xe MRI metrics remained sensitive to diagnosis sub-groups when only patients with normal pulmonary function tests were considered.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
